FDA grants cancer drug regulatory short cut: Can draw on existing data

The first formal meeting with FDA yielded positive feedback to Oncology Venture. The Danish biotech company aims to obtain US approval of its breast cancer candidate and expects to file an application for initiating phase III trials during first half of 2019.

Photo: /ritzau/Lars Krabbe

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles